Live Breaking News & Updates on Vera Therapeutics Company Profile Get Rating

Stay updated with breaking news from Vera therapeutics company profile get rating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Vera Therapeutics, Inc. (NASDAQ:VERA) Expected to Post Q1 2022 Earnings of ($0.67) Per Share

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Rating) – Wedbush issued their Q1 2022 EPS estimates for Vera Therapeutics in a report issued on Monday, April 18th. Wedbush analyst L. Chico anticipates that the company will post earnings per share of ($0.67) for the quarter. Wedbush has a “Outperform” rating and a $32.00 price objective on […] ....

United States , Patrickg Enright , Securities Exchange Commission , Vera Therapeutics Company Profile Get Rating , Vera Therapeutics Inc , Zacks Investment Research , Blackrock Inc , Deutsche Bank , Wells Fargo Company , Citadel Advisors , Vera Therapeutics , Get Rating , Investment Research , State Teachers Retirement System , Director Patrick , Exchange Commission , Therapeutics Company Profile , Nasdaq Vera , Earnings Estimates ,

Wedbush Initiates Coverage on Vera Therapeutics (NASDAQ:VERA)

Equities research analysts at Wedbush began coverage on shares of Vera Therapeutics (NASDAQ:VERA – Get Rating) in a report issued on Monday, The Fly reports. The brokerage set an “outperform” rating on the stock. VERA has been the topic of several other reports. Zacks Investment Research lowered Vera Therapeutics from a “hold” rating to a […] ....

United States , Thomson Reuter , Patrickg Enright , Geode Capital Management , Vera Therapeutics Company Profile Get Rating , Vera Therapeutics Inc , Zacks Investment Research , Blackrock Inc , Deutsche Bank , America Corp , Vera Therapeutics , Get Rating , Investment Research , Director Patrick , Capital Management , Therapeutics Company Profile , Nasdaq Vera , Initiated Coverage ,

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Purchases 333,333 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Rating) Director Patrick G. Enright acquired 333,333 shares of the business’s stock in a transaction dated Thursday, February 10th. The shares were purchased at an average price of $15.00 per share, with a total value of $4,999,995.00. The acquisition was disclosed in a legal filing with the SEC, which […] ....

United States , Patrickg Enright , Vera Therapeutics Company Profile Get Rating , Vera Therapeutics Inc , Zacks Investment Research , Deutsche Bank , American International Group Inc , Citigroup Inc , Vera Therapeutics , Get Rating , Director Patrick , Investment Research , State Teachers Retirement System , International Group , Therapeutics Company Profile , Nasdaq Vera , Insider Trading , Nsider Trades ,

Vera Therapeutics (NASDAQ:VERA) Stock Rating Reaffirmed by Lifesci Capital

Vera Therapeutics (NASDAQ:VERA – Get Rating)‘s stock had its “outperform” rating restated by analysts at Lifesci Capital in a research report issued on Monday, Zacks.com reports. Separately, Zacks Investment Research cut Vera Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, February 8th. One research analyst has rated the stock […] ....

United States , Geode Capital Management , Vera Therapeutics Company Profile Get Rating , Vera Therapeutics Inc , Zacks Investment Research , Blackrock Inc , Citadel Advisors , Millennium Management , Vera Therapeutics , Get Rating , Lifesci Capital , Street Corp , Capital Management , Therapeutics Company Profile , Nasdaq Vera , Reiterated Rating ,